Literature DB >> 7591274

Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma.

N Barboule1, P Mazars, V Baldin, S Vidal, S Jozan, P Martel, A Valette.   

Abstract

The growth-inhibitory protein p21WAF1/CIP1 is a potent inhibitor of various cyclin-dependent kinases, the expression of which is regulated at the transcriptional level by p53-dependent and -independent mechanisms. We examined p21WAF1/CIP1 mRNA and protein expression in 5 human ovarian-adenocarcinoma cell lines, 1 primary culture of normal surface epithelium and 17 human ovarian-tumor specimens. In culture cells, the p21WAF1/CIP1 protein was expressed in normal ovarian epithelial cells and at a high level in the adenocarcinoma 2008 and IGROV-1 cell lines. p21 WAF1/CIP1 expression was undetectable at the mRNA and protein levels in the NIH-OVCAR-3 and SKOV-3 ovarian-adenocarcinoma cell lines which are respectively mutated and deleted in the p53 gene. Heterogeneous expression of p21WAF1/CIP1 observed in ovarian-cancer cell lines in culture was also found in vivo on tumor specimens. p21WAF1/CIP1 expression is undetectable in 25% of the ovarian biopsies examined. Since it has been found that the p53 gene is mutated in 79% of ovarian cancer, the absence of p21WAF1/CIP1 expression in 25% of these ovarian cancer could not be correlated with p53 mutation. The proliferation index of the 17 tumors showed great variation from one tumor to another. However, no significant correlation was found between p21WAF1/CIP1 expression and the proliferation rate of the tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591274     DOI: 10.1002/ijc.2910630502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Toshiro Wakatsuki; Masahide Ikeguchi; Ken Shirabe; Masaru Morita; Yoshihiro Kakeji; Tokujiro Yano; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

2.  p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression.

Authors:  A N Cheung; D H Shen; U S Khoo; L C Wong; H Y Ngan
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

3.  Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo.

Authors:  Jun Zhan; John B Easton; Shile Huang; Ashutosh Mishra; Limin Xiao; Eilyn R Lacy; Richard W Kriwacki; Peter J Houghton
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

Review 4.  The role of the cell cycle in genitourinary carcinoma.

Authors:  T W McGarvey; S B Malkowicz
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.

Authors:  G M Maelandsmo; R Holm; O Fodstad; R S Kerbel; V A Flørenes
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

6.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

Authors:  S Clasen; W A Schulz; C D Gerharz; M O Grimm; F Christoph; B J Schmitz-Dräger
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.

Authors:  M A Anttila; V M Kosma; J Hongxiu; J Puolakka; M Juhola; S Saarikoski; K Syrjänen
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  Thr55 phosphorylation of p21 by MPK38/MELK ameliorates defects in glucose, lipid, and energy metabolism in diet-induced obese mice.

Authors:  Hyun-A Seong; Hyunjung Ha
Journal:  Cell Death Dis       Date:  2019-05-16       Impact factor: 8.469

9.  Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.

Authors:  Seonhyang Jeong; Jandee Lee; Daham Kim; Mi-Youn Seol; Woo Kyung Lee; Jong Ju Jeong; Kee-Hyun Nam; Sang Geun Jung; Dong Yeob Shin; Eun Jig Lee; Woong Youn Chung; Young Suk Jo
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

10.  TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.

Authors:  J Kupryjańczyk; R Madry; J Plisiecka-Hałasa; J Bar; E Kraszewska; I Ziółkowska; A Timorek; J Stelmachów; J Emerich; M Jedryka; A Płuzańska; I Rzepka-Górska; K Urbański; J Zieliński; J Markowska
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.